Mayne Pharma shares on watch after major agreement with Mithra Pharmaceuticals

The Mayne Pharma Group Ltd (ASX:MYX) share price will be on watch today after announcing a major agreement with Mithra Pharmaceuticals…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mayne Pharma Group Ltd (ASX: MYX) share price will be on watch today following the release of a positive announcement this morning.

What did Mayne Pharma announce?

This morning the pharmaceutical company announced that it has signed a 20-year exclusive supply and license agreement with Mithra Pharmaceuticals to commercialise a novel oral contraceptive comprising Estetrol (E4) and drospirenone (DRSP) in the United States.

According to the release, the product is expected to be launched in first half of calendar year 2021, subject to US Food and Drug Administration approval. On approval the product is expected to receive five-year New Chemical Entity (NCE) exclusivity from the regulator, with potential for patent protection beyond 2030.

The release explains that E4/DRSP is a novel, next generation combined oral contraceptive composed of 15 mg E4 and 3 mg DRSP.

While E4 is a native estrogen produced by the human foetal liver during pregnancy, following more than 20 years of research and development, Mithra can now produce it at scale through a complex plant-based production process.

Under the terms of the agreement, Mayne Pharma will pay up to US$295 million comprising US$8.75 million in cash and 4.95% of Mayne Pharma's ordinary shares at closing. The company will also pay US$11 million in cash and a further 4.65% of Mayne Pharma's ordinary shares following FDA approval, plus contingent payments based on reaching cumulative net sales targets.

Mayne Pharma's CEO, Scott Richards, was very pleased with this addition to the company's portfolio.

He said: "I am excited to announce the addition of E4/DRSP, a next generation oral contraceptive, to our specialty brand portfolio and further strengthen our relationship with Mithra, who is also our partner for generic NUVARING. This transaction transforms Mayne Pharma and is highly consistent with our stated strategy to build our specialty business with durable, high growth novel products in core therapeutic categories leveraging our commercial capability and associated know-how in the US."

"If approved, Estetrol (E4) will be the first native estrogen approved in a contraceptive product in the US and the first new estrogen introduced in the US in approximately 50 years. E4/DRSP is an innovative contraceptive with a unique mode of action that phase II and phase III studies suggest could result in improved patient outcomes. This product is expected to be a foundation asset in Women's Health for many years to come and has a strong and synergistic fit with Mayne Pharma's currently marketed portfolio of more than 20 branded generic contraceptives and existing pipeline products such as generic NUVARING for which we are targeting approval in calendar 2020," he added.

There certainly is a large market opportunity for the drug. Management revealed that the US contraceptive market is valued at US$5.4 billion, with the short acting combined hormonal contraceptives component estimated at US$4 billion and approximately 135 million units sold annually.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Record Highs

The ASX 200 Index is on its way to another all-time high today. Here's why

These blue chip stocks are driving the index towards a new record today...

Read more »

Group of friends trading stocks on their phones. symbolising the 3 most traded ASX 200 shares today
Share Market News

3 ASX mining stocks topping the most-traded list in October

Chinese stimulus news and company announcements likely contributed to the higher trading activity.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »